	US 12,492,257 B2
	Anti-CTLA-4 antibodies and methods of use thereof
Marc Van Dijk, Bosch en Duin (NL); Cornelia Anne Mundt, Lörrach (DE); Gerd Ritter, New York, NY (US); David Schaer, Mamaroneck, NY (US); Jedd David Wolchok, New York, NY (US); Taha Merghoub, Jersey City, NJ (US); David Adam Savitsky, Boxford, MA (US); and Nicholas Stuart Wilson, San Carlos, CA (US)
Assigned to AGENUS INC., Lexington, MA (US); LUDWIG INSTITUTE FOR CANCER RESEARCH LTD., Zurich (CH); and MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US)
Filed by AGENUS INC., Lexington, MA (US); Ludwig Institute for Cancer Research Ltd., Zurich (CH); and Memorial Sloan-Kettering Cancer Center, New York, NY (US)
Filed on Jan. 24, 2022, as Appl. No. 17/582,839.
Application 17/582,839 is a continuation of application No. 16/858,195, filed on Apr. 24, 2020, granted, now 11,267,889.
Application 16/858,195 is a continuation of application No. 16/572,216, filed on Sep. 16, 2019, abandoned.
Application 16/572,216 is a continuation of application No. 16/165,833, filed on Oct. 19, 2018, granted, now 10,479,833, issued on Nov. 19, 2019.
Application 16/165,833 is a continuation of application No. 15/166,305, filed on May 27, 2016, granted, now 10,144,779, issued on Dec. 4, 2018.
Claims priority of provisional application 62/323,226, filed on Apr. 15, 2016.
Claims priority of provisional application 62/294,558, filed on Feb. 12, 2016.
Claims priority of provisional application 62/292,500, filed on Feb. 8, 2016.
Claims priority of provisional application 62/280,263, filed on Jan. 19, 2016.
Claims priority of provisional application 62/257,202, filed on Nov. 18, 2015.
Claims priority of provisional application 62/190,653, filed on Jul. 9, 2015.
Claims priority of provisional application 62/182,363, filed on Jun. 19, 2015.
Claims priority of provisional application 62/168,391, filed on May 29, 2015.
Prior Publication US 2022/0267443 A1, Aug. 25, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61K 51/10 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01); C12N 15/85 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2818 (2013.01) [A61K 47/6849 (2017.08); A61K 51/1027 (2013.01); A61P 35/00 (2018.01); A61P 37/04 (2018.01); C07K 16/283 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

20 Claims

1. A host cell comprising:

(a) a first isolated polynucleotide encoding an antibody heavy chain variable region of an antibody that specifically binds human CTLA-4 protein, wherein the antibody heavy chain variable region comprises complementarity determining regions CDRH1, CDRH2, and CDRH3, wherein

(i) CDRH1 comprises the amino acid sequence of SYX₁MX₂(SEQ ID NO: 22), wherein

X₁is S or A; and

X₂is N or S;

(ii) CDRH2 comprises the amino acid sequence of SISSSSSYIYYADSVKG (SEQ ID NO: 2); and

(iii) CDRH3 comprises the amino acid sequence of VGLMGPFXI (SEQ ID NO: 23),

wherein

X is D or N; and

(b) a second isolated polynucleotide encoding an antibody light chain variable region of an antibody that specifically binds human CTLA-4 protein, wherein the antibody light chain variable region comprises complementarity determining regions CDRL1, CDRL2, and CDRL3, wherein

(i) CDRL1 comprises the amino acid sequence of RASQSVX₁X₂YLX₃(SEQ ID NO: 24),

wherein:

X₁is S or G;

X₂is R, S, or T; and

X₃is G or A;

(ii) CDRL2 comprises the amino acid sequence of X₁X₂SX₃RAT (SEQ ID NO: 25),

wherein:

X₁is G or A;

X₂is A or T; and

X₃is T, S, R, or N; and

(iii) CDRL3 comprises the amino acid sequence of QQYGX₁SPX₂T (SEQ ID NO: 26),

wherein:

X₁is S or T; and

X₂is W or F.